ArticleBioengineering (Basel, Switzerland)2026
Pre-Deployment Audit of Actionability and Equity in Severe Tooth Loss Prediction Using Constrained Algorithmic Recourse and Temporal Validation.
Article in Bioengineering (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPredictive performance does not establish whether model-identified risks correspond to feasible, equitable pathways. We assessed the actionability and equity of a severe tooth loss prediction model using constrained algorithmic recourse and same-source temporal validation.
methodsAn Explainable Boosting Machine was trained using 2022 Behavioral Risk Factor Surveillance System data from 433,772 adults. High-risk adults underwent recourse auditing incorporating immutability locks, behavioral directionality, physiological safety floors, and at most three feature changes. Recourse represented hypothetical movement within model space, not treatment advice, causal risk reduction, or reversal of tooth loss. Primary reachability was the unweighted analytic-cohort proportion for which the frozen engine identified a feasible pathway; a BRFSS survey-weighted domain sensitivity analysis used final weights, strata, and primary sampling units. The audit separated reachability from conditional burden among reachable adults. Equity was evaluated across Social Indicators of Disparity Index (SIDI) and income strata using Oaxaca-Blinder decomposition. The frozen specification was evaluated in a 2022 holdout and the 2024 BRFSS cohort (
resultsSurvey-weighted areas under the receiver operating characteristic curve were 0.858, 0.855, and 0.858 in the 2022 full, 2022 holdout, and 2024 cohorts. Primary unweighted reachability was 10.61%, 10.54%, and 9.82%; corresponding survey-weighted estimates were 12.69% (95% design-aware CI, 12.33-13.07%), 12.31% (11.54-13.12%), and 11.30% (10.95-11.65%), respectively. Thus, reachability remained limited under both estimands. The high-SIDI group showed poorer calibration. Under the prespecified primary SIDI-neutral additive-cost specification, residual conditional cost differences across SIDI strata were small; alternative burden metrics were direction-dependent. The income residual attenuated from the 2022 holdout to 2024, although its confidence intervals were fixed-pipeline row-bootstrap intervals rather than fully design-based intervals.
conclusionsStable predictive performance masked limited model-space actionability. Integrating explicitly labeled reachability estimands, conditional burden, equity, and temporal transport can strengthen pre-deployment evaluation. Because severe tooth loss is irreversible, recourse pathways should be interpreted as a stress test of model-implied modifiable factors rather than evidence of reversibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.